"dNDAs"
This article was originally published in The Tan Sheet
Executive Summary
Approved Rid Mousse "NDA Deviation" may open the door to other such applications being filed with the agency, FDA indicates (1"The Tan Sheet" March 13, p. 4). "dNDAs" allow an applicant to file only that data supporting the proposed change to a monograph drug, such as a new formulation, rather than all of the data required under an NDA. According to FDA regulations, "A new drug application requesting approval of an OTC drug deviating in any respect from a monograph that has become final shall be in the form required by Sec. 314.50 of this chapter, but shall include a statement that the product meets all the conditions of the applicable monograph except for the deviation for which approval is requested and may omit all information except that pertinent to the deviation"
You may also be interested in...
Pfizer Rid Mousse Pediculicide Approved Under "NDA Deviation"
FDA approved an "NDA Deviation" (21-043) for Pfizer's Maximum Strength Rid Mousse aerosolized foam lice treatment March 7. It is one of the first "NDA Deviations" to get the go-ahead from the agency; such an application is for a product that is comparable to products in a monograph but deviates in a significant way.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands